Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: giant cell arteritis

Consensus Guidelines on Diagnostic Approach to Giant Cell Arteritis Arrive from Society for Cardiovascular Pathology

Moayad Alqazlan, MBBS, Vidhya Nair, MBBS, MD, & Michael A. Seidman, MD, PhD  |  July 9, 2024

At the end of 2023, the Society for Cardiovascular Pathology (SCVP) published consensus guidelines on the diagnostic approach to temporal artery biopsy.1 Through this publication, SCVP hopes to bring more uniformity to the processing, interpretation and reporting of these specimens, taking into consideration the most up-to-date literature available. These guidelines have obvious impact on clinical…

Filed under:ConditionsGuidelinesOpinionSpeak Out RheumVasculitis Tagged with:Giant Cell Arteritisgiant cell arteritis (GCA)temporal artery biopsy

How Prevalent Is Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica?

Colm Kirby, MB, BCh, BAO, MRCPI, Rachael Flood, MB, BCh, BAO, MRCPI, Ronan Mullan, MB, BCh, BAO, MRCPI, Grainne Murphy, MB, BCh, BAO, MRCPI, & David Kane, MB, BCh, BAO, MRCPI  |  January 24, 2024

Background/Purpose It has been reported that 20–50% of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). The natural history of ultrasound-defined subclinical GCA in PMR is not known. Methods Twenty-five newly diagnosed PMR patients who met a clinical diagnosis for PMR, verified by two rheumatologists, were examined by ultrasound. All six branches…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch RheumVasculitis Tagged with:Giant Cell Arteritisgiant cell arteritis (GCA)glucocorticoid resistantimagingPMR FocusRheumPolymyalgia RheumaticaResearch Review

Case Report: Giant Cell Arteritis-Related Stroke

Jessica Meek, MD, Anna Coppinger, DO, & Sejal Khan, DO  |  September 10, 2023

Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

Filed under:ConditionsHome SliderVasculitis Tagged with:case reportGCAgiant cell arteritis (GCA)stroke

Vasculitis Guidelines in Focus, Part 6: Giant Cell Arteritis

Michael Putman, MD  |  September 27, 2022

In 2021, the ACR—in concert with the Vasculitis Foundation (VF)—released four new vasculitis guidelines, one each on: 1) anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, 2) giant cell arteritis (GCA) and Takayasu arteritis, 3) polyarteritis nodosa and 4) Kawasaki disease. The guideline development process is complex. For the vasculitis guidelines, this process kicked off in June…

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:GCAgiant cell arteritis (GCA)guidelineVasculitis

Case Report: A Rare Mimic of Giant Cell Arteritis

Iryna Nemesh, MD, Saleema Kherani, MD MPH, Shikha Singla, MD, & William Wirostko, MD  |  November 14, 2021

Syphilis is a chronic sexually transmitted disease (STD) caused by the spirochete Treponema pallidum. The clinical manifestations of syphilis are divided into four stages: 1) the primary stage, characterized by painless mucosal or cutaneous chancre at the site of infection that resolves spontaneously; 2) the secondary stage in which a generalized maculopapular rash and condyloma…

Filed under:ConditionsVasculitis Tagged with:ocular diseasesyphilis

Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

Atypical Giant Cell Arteritis Case Illustrates Diagnosis, Management Challenges

Ashraf Raslan, MD, Dorian Infantino, MD, Roman Zuckerman, DO, & Daniel Berlin, MD  |  November 14, 2021

Giant cell arteritis (GCA) is a granulomatous vasculitis of large- and medium-sized arteries, usually affecting the cranial branches of the aortic arch. It is the most common vasculitis, with the highest risk factor being age. Accurate diagnosis and prompt initiation of therapy are of great importance to prevent serious complications, with the most feared being…

Filed under:ConditionsVasculitis Tagged with:case reportGiant Cell Arteritistocilizumab

Varicella Zoster Virus Not Associated with Giant Cell Arteritis Pathogenesis

Carina Stanton  |  February 4, 2020

Researchers suggest antiviral therapy is not appropriate for patients with GCA, based on their study findings and related research…

Filed under:ConditionsVasculitis Tagged with:GCAgiant cell arteritis (GCA)varicella zoster virus

New Insights into the Management of Giant Cell Arteritis

Lara C. Pullen, PhD  |  January 28, 2020

A systematic literature review identified novel evidence on the treatment and management of GCA that was incorporated into the most recent EULAR recommendations on the management of large vessel vasculitis. Investigators confirmed the efficacy of prompt initiation of glucocorticoids and found fast-track approaches to diagnosis lowered the risk of ischemic complications…

Filed under:ConditionsEULAR/OtherMeeting ReportsVasculitis Tagged with:EULARGCAgiant cell arteritis (GCA)guidelinelarge-vessel vasculitisrecommendationstocilizumab

Race May Not Be a Risk Factor for Giant Cell Arteritis

Lara C. Pullen, PhD  |  October 21, 2019

Past research has identified being of Northern European descent as a risk factor, among others such as age, sex and HLA DRB1, for developing giant cell arteritis (GCA). But new research casts doubts on this idea, finding that rates of biopsy proven GCA may not differ by race…

Filed under:ConditionsVasculitis Tagged with:GCAgiant cell arteritis (GCA)raceRisk Factors

Permanent Vision Loss in Late Giant Cell Arteritis

Kimberly Retzlaff  |  October 18, 2018

Patients with polymyalgia rheumatica (PMR) or peripheral arthritis may require extra vigilance during treatment because of a suspected link to giant cell arteritis (GCA) and, potentially, permanent vision loss. “Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study,” a March 2018 study published in The Journal of Rheumatology, suggests…

Filed under:ConditionsVasculitis Tagged with:peripheral arthritisPolymyalgia Rheumaticavision lossvisual loss

  • 1
  • 2
  • 3
  • …
  • 18
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences